Windlas Biotech Limited (WINDLAS) - Total Liabilities

Latest as of September 2025: Rs2.80 Billion INR ≈ $30.29 Million USD

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has total liabilities worth Rs2.80 Billion INR (≈ $30.29 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Windlas Biotech Limited to track the company's year-over-year net asset growth rate.

Windlas Biotech Limited - Total Liabilities Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Windlas Biotech Limited to measure how efficiently the company converts operating cash flow to free cash.

Windlas Biotech Limited Competitors by Total Liabilities

The table below lists competitors of Windlas Biotech Limited ranked by their total liabilities.

Company Country Total Liabilities
Nippon Indosari Corpindo Tbk
JK:ROTI
Indonesia Rp1.79 Trillion
Inesa Intelligent Tech Inc B
SHG:900901
China $2.89 Billion
Invivyd Inc.
NASDAQ:IVVD
USA $38.69 Million
Usun Technology Co Ltd
TWO:3498
Taiwan NT$1.80 Billion
RCI Hospitality Holdings Inc
NASDAQ:RICK
USA $328.11 Million
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
France €11.62 Billion
Onward Medical N.V.
BR:ONWD
Belgium €29.24 Million

Liability Composition Analysis (2018–2025)

This chart breaks down Windlas Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Windlas Biotech Limited (WINDLAS) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.52 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Windlas Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Windlas Biotech Limited (2018–2025)

The table below shows the annual total liabilities of Windlas Biotech Limited from 2018 to 2025.

Year Total Liabilities Change
2025-03-31 Rs2.55 Billion
≈ $27.54 Million
+44.48%
2024-03-31 Rs1.76 Billion
≈ $19.06 Million
+39.12%
2023-03-31 Rs1.27 Billion
≈ $13.70 Million
+31.66%
2022-03-31 Rs962.33 Million
≈ $10.41 Million
-0.79%
2021-03-31 Rs970.04 Million
≈ $10.49 Million
-24.70%
2020-03-31 Rs1.29 Billion
≈ $13.93 Million
+23.17%
2019-03-31 Rs1.05 Billion
≈ $11.31 Million
-36.55%
2018-03-31 Rs1.65 Billion
≈ $17.83 Million
--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic
Market Cap
$200.70 Million
Rs18.56 Billion INR
Market Cap Rank
#16505 Global
#869 in India
Share Price
Rs880.50
Change (1 day)
+1.03%
52-Week Range
Rs718.35 - Rs1070.80
All Time High
Rs1144.25
About

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more